Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FARICIMAB-SVOA for Polypoidal choroidal vasculopathy: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where FARICIMAB-SVOA was used for Polypoidal choroidal vasculopathy.

Most Reported Side Effects for FARICIMAB-SVOA

Side Effect Reports % Deaths Hosp.
Off label use 453 23.7% 27 28
No adverse event 259 13.6% 0 0
Death 158 8.3% 153 1
Visual impairment 146 7.7% 1 15
Eye inflammation 136 7.1% 0 5
Blindness 127 6.7% 0 8
Endophthalmitis 125 6.6% 1 9
Uveitis 102 5.4% 0 12
Vitritis 90 4.7% 0 13
Drug ineffective 82 4.3% 0 3
Vision blurred 80 4.2% 0 10
Iridocyclitis 76 4.0% 0 9
Vitreous floaters 65 3.4% 0 3
Eye pain 61 3.2% 0 10
Retinal haemorrhage 51 2.7% 0 3

Other Indications for FARICIMAB-SVOA

Neovascular age-related macular degeneration (725) Product used for unknown indication (473) Diabetic retinal oedema (256) Age-related macular degeneration (117) Retinal vein occlusion (104) Macular oedema (77) Diabetic retinopathy (71) Macular degeneration (67) Choroidal neovascularisation (65) Dry age-related macular degeneration (19)

Other Drugs Used for Polypoidal choroidal vasculopathy

RANIBIZUMAB (315) VERTEPORFIN (210) AFLIBERCEPT (193) BROLUCIZUMAB (70) BROLUCIZUMAB-DBLL (64) BEVACIZUMAB (46) FARICIMAB\FARICIMAB-SVOA (43) FLUOROURACIL (17) IRINOTECAN (17) LEUCOVORIN (17)

Related Pages

FARICIMAB-SVOA Full Profile All Polypoidal choroidal vasculopathy Drugs FARICIMAB-SVOA Demographics FARICIMAB-SVOA Timeline